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Eﬀ ect of tamoxifen and radiotherapy in women with locally 
excised ductal carcinoma in situ: long-term results from the 
UK/ANZ DCIS trial
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William D George
Summary
Background Initial results of the UK/ANZ DCIS (UK, Australia, and New Zealand ductal carcinoma in situ) trial 
suggested that radiotherapy reduced new breast events of ipsilateral invasive and ductal carcinoma in situ (DCIS) 
compared with no radiotherapy, but no signiﬁ cant eﬀ ects were noted with tamoxifen. Here, we report long-term 
results of this trial.
Methods Women with completely locally excised DCIS were recruited into a randomised 2×2 factorial trial of 
radiotherapy, tamoxifen, or both. Randomisation was independently done for each of the two treatments (radiotherapy 
and tamoxifen), stratiﬁ ed by screening assessment centre, and blocked in groups of four. The recommended dose for 
radiation was 50 Gy in 25 fractions over 5 weeks (2 Gy per day on weekdays), and tamoxifen was prescribed at a dose of 
20 mg daily for 5 years. Elective decision to withhold or provide one of the treatments was permitted. The endpoints of 
primary interest were invasive ipsilateral new breast events for the radiotherapy comparison and any new breast event, 
including contralateral disease and DCIS, for tamoxifen. Analysis of each of the two treatment comparisons was 
restricted to patients who were randomly assigned to that treatment. Analyses were by intention to treat. All trial drugs 
have been completed and this study is in long-term follow-up. This study is registered, number ISRCTN99513870.
Findings Between May, 1990, and August, 1998, 1701 women were randomly assigned to radiotherapy and tamoxifen, 
radiotherapy alone, tamoxifen alone, or to no adjuvant treatment. Seven patients had protocol violations and thus 
1694 patients were available for analysis. After a median follow-up of 12·7 years (IQR 10·9–14·7), 376 (163 invasive 
[122 ipsilateral vs 39 contralateral], 197 DCIS [174 ipsilateral vs 17 contralateral], and 16 of unknown invasiveness or 
laterality) breast cancers were diagnosed. Radiotherapy reduced the incidence of all new breast events (hazard ratio 
[HR] 0·41, 95% CI 0·30–0·56; p<0·0001), reducing the incidence of ipsilateral invasive disease (0·32, 0·19–0·56; 
p<0·0001) as well as ipsilateral DCIS (0·38, 0·22–0·63; p<0·0001), but having no eﬀ ect on contralateral breast cancer 
(0·84, 0·45–1·58; p=0·6). Tamoxifen reduced the incidence of all new breast events (HR 0·71, 95% CI 0·58–0·88; 
p=0·002), reducing recurrent ipsilateral DCIS (0·70, 0·51–0·86; p=0·03) and contralateral tumours (0·44, 0·25–0·77; 
p=0·005), but having no eﬀ ect on ipsilateral invasive disease (0·95, 0·66–1·38; p=0·8). No data on adverse events 
except cause of death were collected for this trial.
Interpretation This updated analysis conﬁ rms the long-term beneﬁ cial eﬀ ect of radiotherapy and reports a beneﬁ t for 
tamoxifen in reducing local and contralateral new breast events for women with DCIS treated by complete local excision.
Funding Cancer Research UK and the Australian National Health and Medical Research Council.
Introduction
Ductal carcinoma in situ (DCIS) is usually an 
asymptomatic disorder that is characterised by a clonal 
proliferation of epithelial cells conﬁ ned within the 
lumen of mammary ducts.1,2 Screening has led to a 
substantial increase in the incidence of DCIS over the 
past two decades; the disorder represents 10% of all 
breast carcinomas and around 20% of screen-detected 
cancers.3–5
Management options for DCIS include surgery, 
radiotherapy, and hormonal therapy.6 The eﬀ ectiveness of 
radiotherapy in reducing recurrences has been examined 
in four clinical trials.7–11 In all these studies, radiotherapy 
reduced in-situ or invasive recurrences by about 50%. 
Although radiotherapy is associated with substantial 
reductions in local recurrence, no diﬀ erences have been 
reported in metastatic disease or overall survival.12,13
The role of tamoxifen in the management of DCIS has 
been investigated in the UK, Australia, and New Zealand 
(UK/ANZ) DCIS trial10 and also in the National Surgical 
Adjuvant Breast and Bowel Project B-24 (NSABP B-24) 
trial.14 In the NSABP trial, patients with DCIS received 
radiotherapy and were then randomised to tamoxifen 
(20 mg/day) or placebo. After just over 6 years of follow-up, 
a signiﬁ cant reduction in all new breast events was reported 
in the tamoxifen group compared with the placebo group 
(rate ratio 0·63, 95% CI 0·47–0·83; p=0·0009). The use of 
other endocrine treatments for DCIS is under investigation 
in the International Breast Cancer Intervention Study II 
(IBIS-II) and the NSABP B-35 trial.15
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Figure 1: Trial proﬁ le 
T=tamoxifen. R=radiotherapy. CT=control group for tamoxifen. CR=control group for radiotherapy. 
7 excluded
1701 patients
randomised
912 chose to enter 2×2
randomisation
782 chose randomisation
to one of the
treatments
664 made choice about
radiotherapy and
only randomised
to tamoxifen 
603 elected not to have
radiotherapy
242 randomised to
radiotherapy and
tamoxifen (T, R)
224 randomised to
tamoxifen only
(T, CR)
220 randomised to
radiotherapy
only (CT, R)
226 randomised to no
treatment (CT, CR)
305 randomised to no
tamoxifen (CT, −)
31 randomised to no
tamoxifen (CT, −)
30 randomised to
tamoxifen (T, −)
298 randomised to
tamoxifen (T, −)
61 elected to have
radiotherapy
13 randomised to no
radiotherapy (−, CR)
16 randomised to
radiotherapy (−, R)
45 randomised to no
radiotherapy (−, CR)
44 randomised to
radiotherapy (−, R)
29 elected not to
receive tamoxifen
89 elected to have
tamoxifen
118 made choice about
tamoxifen and only
randomised to
radiotherapy
1694 eligible for
analysis
No adjuvant 
treatment (n=544)
Tamoxifen alone 
(n=567)
Radiotherapy alone 
(n=267)
Radiotherapy and 
tamoxifen (n=316)
Total (n=1694)
Follow-up (woman-years) 5428 6017 3023 3545 18 013
Breast events 174 (32%) 135 (24%) 35 (13%) 32 (10%) 376 (22%)
DCIS 96 (18%) 72 (13%) 16 (6%) 13 (4%) 197 (12%)
Ipsilateral 86 (16%) 63 (11%) 14 (5%) 11 (3%) 174 (10%)
Contralateral 9 (2%) 4 (1%) 2 (1%) 2 (1%) 17 (1%)
Unknown 1 5 0 0 6
Invasive 72 (13%) 57 (10%) 16 (6%) 18 (6%) 163 (10%)
Ipsilateral 52 (10%) 49 (9%) 10 (4%) 11 (3%) 122 (7%)
Contralateral 20 (4%) 7 (1%) 5 (2%) 7 (2%) 39 (2%)
Unknown 0 1 1 0 2
Unknown 6 (1%) 6 (1%) 3 (1%) 1 (0%) 16 (1%)
Annual rate of breast events (%) 3·2% 2·2% 1·2% 0·9% 2·1%
Data are number (%). DCIS=ductal carcinoma in situ.
Table 1: New breast events
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The UK/ANZ DCIS trial was a 2×2 factorial randomised 
trial that assessed radiotherapy, tamoxifen, or both in 
patients with completely excised DCIS.10 After a median 
follow-up of 4·4 years (range 0·2–9·9), patients who had 
radiotherapy had a lower incidence of ipsilateral invasive 
disease (hazard ratio [HR] 0·45, 95% CI 0·24–0·85) and 
ipsilateral DCIS (0·36, 0·19–0·66) than those who did 
not have radiotherapy, but there was no diﬀ erence in 
contralateral disease between groups. Tamoxifen was 
weakly associated with a reduction in all new breast 
events compared with no tamoxifen (HR 0·83, 95% CI 
0·64–1·06), but this was because of a reduction in all 
DCIS (0·68, 0·49–0·96); no reduction in invasive cancer 
was reported (1·11, 0·76–1·63). Here, we report updated 
results of the UK/ANZ DCIS trial with a median follow-
up of 12·7 years.
Methods
Patients
Patients with unilateral or bilateral DCIS (>90% detected 
in the national breast screening programme) who were 
deemed suitable for breast conservation were entered 
into the trial. Patients with lobular carcinoma in situ, 
atypical ductal hyperplasia in the absence of DCIS, 
Paget’s disease of the nipple, and those in whom 
pathological margins of the disease were uncertain were 
excluded, as were patients with a reduced life 
expectancy.
Patients were included if their lesion or lesions could 
be completely excised, which was conﬁ rmed by radiology 
of the surgical specimen and free margins on histological 
examination. If DCIS extended to the margin of the 
Randomised 
to 
tamoxifen 
(n=794)
Randomised 
to no 
tamoxifen 
(n=782)
Hazard ratio 
(95% CI)
p value
All patients
Ipsilateral 129 (15·7%) 162 (19·6%) 0·78 (0·62–0·99) 0·04
Invasive 56 (6·8%) 60 (6·9%) 0·95 (0·66–1·38) 0·79
DCIS 70 (8·6%) 97 (12·1%) 0·70 (0·51–0·86) 0·03
Unknown 3 5 ·· ··
Contralateral 17 (1·9%) 38 (4·2%) 0·44 (0·25–0·77) 0·005
Invasive 12 (1·5%) 25 (2·7%) 0·47 (0·24–0·94) 0·03
DCIS 4 (0·3%) 11 (1·3%) 0·36 (0·11–1·12) 0·08
Unknown 1 2 ·· ··
All invasive 69 (8·5%) 85 (9·1%) 0·81 (0·59–1·12) 0·2
All DCIS 77 (9·2%) 111 (13·6%) 0·67 (0·50–0·90) 0·008
All 
unknown*
5 8 ·· ··
All new 
breast events
151 (18·1%) 204 (24·6%) 0·71 (0·58–0·88) 0·002
Patients not receiving radiotherapy (n=1053)
Ipsilateral 109 (13·2%) 140 (17·0%) 0·77 (0·59–0·98) 0·04
Invasive 46 (5·5%) 51 (6·0%) 0·89 (0·59–1·33) 0·6
DCIS 60 (7·4%) 84 (10·4%) 0·71 (0·51–0·99) 0·04
Unknown 3 5 ·· ··
Contralateral 8 (0·9%) 29 (3·1%) 0·27 (0·12–0·59) 0·001
Invasive 6 (0·8%) 20 (2·0%) 0·29 (0·12–0·73) 0·009
DCIS 2 (0·0%) 9 (1·0%) 0·22 (0·05–1·01) 0·05
Unknown 0 0 ·· ··
All 
unknown†
5 2 ·· ··
All new 
breast events
122 (14·6%) 171 (20·7%) 0·71 (0·57–0·87) 0·001
Patients receiving radiotherapy (n=523)
Ipsilateral 20 (2·4%) 22 (2·6%) 0·93 (0·50–1·75) 0·8
Invasive 10 (1·3%) 9 (0·9%) 1·41 (0·54–3·70) 0·5
DCIS 10 (1·1%) 13 (1·7%) 0·68 (0·29–1·59) 0·4
Unknown 0 0 ·· ··
Contralateral 9 (1·1%) 9 (1·1%) 0·99 (0·39–2·49) 1·0
Invasive 6 (0·8%) 5 (0·6%) 1·18 (0·36–3·87) 1·0
DCIS 2 (0·1%) 2 (0·2%) 0·99 (0·14–7·04) 0·8
Unknown 1 2 ·· ··
All 
unknown†
0 2 ·· ··
All new 
breast events
29 (4·1%) 33 (5·6%) 0·99 (0·61–1·59) 0·8
Data are number (%). DCIS=ductal carcinoma in situ. *Laterality or invasiveness 
unknown. †Laterality unknown. 
Table 2: New breast events and 10-year estimates of percentages with 
an event in patients randomised to tamoxifen or not
Figure 2: Kaplan-Meier curve for cumulative incidence and annual hazard 
plot of all breast events in the tamoxifen comparison
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specimen, re-excision was done to establish clear 
margins. The size of lesion, pathological type of disease, 
and if re-excision was done was recorded, and an estimate 
of the maximum diameter of the total lesion was made. 
On an individual basis, surgeons in discussion with each 
patient decided whether to enter the patient into the four-
way 2×2 randomisation, or one of two separate two-way 
randomisations with elective choice for the other 
treatment modality.
Patients were given information that described the 
disease, treatment options, and trial design. Patients 
provided written or verbal consent witnessed by a third 
party before entry into the trial. Ethics approval was 
obtained from local ethics committees at all participating 
hospitals.
Randomisation and masking
Randomisation was done in one of three central trials 
oﬃ  ces by fax or telephone contact. Randomisation was 
independently done for each of the two treatments 
(radiotherapy and tamoxifen), stratiﬁ ed by screening 
assessment centre, and blocked in groups of four. The 
central trial centres each prepared their own 
randomisation lists using a common algorithm, and 
these lists were available only to trial staﬀ  who were 
trained in the randomisation procedure. Tamoxifen and 
radiotherapy were both given open label. 
Procedures
The recommended dose for radiotherapy was 50 Gy in 
25 fractions over 5 weeks (2 Gy per day on weekdays; 
tumour dose fractionation 82) at the isocentre or at the 
point of intersection of the two tangential ﬁ elds. We did 
not recommend boost treatment at the excision site. 
Tamoxifen was prescribed at a dose of 20 mg daily for 
5 years.
Yearly bilateral mammography was recommended for 
the ﬁ rst 7 years after treatment and every 2 years 
thereafter. Dates and sites of histologically conﬁ rmed 
local new breast events (DCIS or invasive cancer), 
diagnosis of any new non-breast malignant disease, and 
causes of death were recorded. Patients in the UK who 
were lost to follow-up were registered with the Oﬃ  ce for 
National Statistics (now the NHS Information Centre) to 
ﬁ nd out details of death (date and cause) and cancer 
registrations (date of registration).
The endpoints of primary interest were invasive 
ipsilateral new breast events for radiotherapy and any 
new breast event, including contralateral disease and 
DCIS for tamoxifen. We also individually assessed the 
eﬀ ects of tamoxifen or radiotherapy on both recurrent 
DCIS or invasive ipsilateral breast cancer and contra-
lateral DCIS or invasive cancer. We also measured distant 
new breast events as a ﬁ rst event, death after new breast 
events (breast cancer death), and cause-speciﬁ c mortality. 
No data on adverse events were routinely collected, except 
for cause of death.
Statistical analysis
To assess the eﬀ ects of the two main treatment 
comparisons, analysis was restricted to patients who 
were randomly assigned to each main treatment 
comparison. Hence, for the tamoxifen comparison only 
patients who were randomly assigned to receive 
tamoxifen or not were included in the analysis. In the 
same way, patients who chose to receive radiotherapy or 
not were excluded from the main radiotherapy 
comparison. Thus, treatment comparisons were not 
confounded by the alternate treatment. All analyses were 
stratiﬁ ed according to whether or not patients received 
the alternate treatment, and whether this was by choice 
or as a result of random treatment allocation. Only the 
ﬁ rst new breast event was recorded; thus, for example, a 
distant new breast event that occurred after a local new 
breast event was not available for analysis.
Analyses were by intention to treat. We compared 
groups by the Cox proportional hazard model to 
estimate HRs, 95% CIs and two-sided p values. 10-year 
estimates and time-to-recurrence curves were produced 
with the Kaplan-Meier method. A p value of less than or 
Figure 3: Forest plot for new breast events in the tamoxifen comparison stratiﬁ ed by whether or not patients 
received radiotherapy
HR=hazard ratio. DCIS=ductal carcinoma in situ. 
HR (95% CI)No tamoxifen
(n/N)
Tamoxifen
(n/N)
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   Invasive
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All
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46/794
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8/794
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140/782
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9/782
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171/782
0·89 (0·59–1·33)
0·71 (0·51–0·99)
0·77 (0·59–0·98)
0·29 (0·12–0·73)
0·22 (0·05–1·01)
0·27 (0·12–0·59)
0·71 (0·57–0·87)
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   Invasive
   DCIS
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All
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0·68 (0·29–1·59)
0·93 (0·50–1·75)
1·18 (0·36–3·87)
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0·99 (0·39–2·49)
0·99 (0·61–1·59)
0·1 0·2
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0·5 1 2
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equal to 0·05 was deemed signiﬁ cant. All calculations 
were done using Stata software (version 10.1).
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN99513870.
Role of the funding source
The trial was developed by the breast cancer 
subcommittee of the UKCCCR (United Kingdom 
Coordinating Committee on Cancer Research; now the 
National Cancer Research Institute [NCRI]) and done 
through three trial oﬃ  ces (Cancer Research UK and 
University College London Cancer Trials Centre, 
London, UK; the Scottish Cancer Therapy Network, 
Edinburgh, UK; and the Australia and New Zealand 
Cancer Trials Oﬃ  ce, Newcastle, NSW, Australia). The 
independent statistician (JC) had full access to all the 
data in the study and was responsible for providing 
regular information to the independent data monitoring 
committee. All authors were responsible for data 
interpretation, writing of the report, and ﬁ nal approval 
of the manuscript for submission. The corresponding 
author had ﬁ nal responsibility for the decision to submit 
for publication. The funding source had no role in the 
decision to publish this report.
Results
Between May, 1990, and August, 1998, 1701 patients were 
randomised in the UK DCIS trial (879 from the UK Trials 
Centre, 635 from the Scottish Trials Centre, and 187 from 
the Australia and New Zealand Trials Centre). After 
randomisation, seven patients were excluded from the 
Randomised 
to 
radiotherapy 
(n=522)
Randomised 
to no 
radiotherapy 
(n=508)
Hazard ratio 
(95% CI)
p value
All patients
Ipsilateral 40 (7·1%) 105 (19·4%) 0·32 (0·22–0·47) <0·0001
Invasive 19 (3·3%) 50 (9·1%) 0·32 (0·19–0·56) <0·0001
DCIS 21 (3·8%) 51 (9·7%) 0·38 (0·22–0·63) <0·0001
Unknown 0 4 ·· ··
Contralateral 18 (3·3%) 21 (4·1%) 0·84 (0·45–1·58) 0·6
Invasive 11 (2·1%) 12 (2·8%) 0·90 (0·40–2·05) 0·8
DCIS 4 (0·6%) 9 (1·4%) 0·43 (0·13–1·41) 0·2
Unknown 3 0 ·· ··
All invasive 31 (5·6%) 62 (10·1%) 0·46 (0·30–0·72) 0·001
All DCIS 26 (4·0%) 63 (11·6%) 0·38 (0·24–0·60) <0·0001
All 
unknown*
3 4 ·· ··
All new 
breast 
events
60 (10·6%) 129 (23·2%) 0·41 (0·30–0·56) <0·0001
Patients not receiving tamoxifen (n=475)
Ipsilateral 21 (4·0%) 59 (11·6%) 0·31 (0·18–0·52) <0·0001
Invasive 9 (1·3%) 28 (4·9%) 0·24 (0·11–0·55) 0·001
DCIS 12 (2·3%) 29 (5·4%) 0·41 (0·21–0·81) 0·01
Unknown 0 2 ·· ··
Contralateral 9 (1·7%) 13 (2·8%) 0·68 (0·29–1·59) 0·4
Invasive 5 (1·0%) 7 (1·0%) 0·71 (0·22–2·23) 0·6
DCIS 2 (0·4%) 6 (1·0%) 0·33 (0·10–1·61) 0·2
Unknown 2 0 ·· ··
All 
unknown†
2 0 ·· ··
All new 
breast 
events
32 (6·0%) 72 (13·1%) 0·41 (0·30–0·57) <0·0001
Patients receiving tamoxifen (n=555)
Ipsilateral 19 (3·4%) 46 (8·7%) 0·37 (0·22–0·64) <0·0001
Invasive 10 (1·9%) 22 (4·1%) 0·44 (0·21–0·93) 0·03
DCIS 9 (1·5%) 22 (4·3%) 0·35 (0·16–0·78) 0·01
Unknown 0 2 ·· ··
Contralateral 9 (1·5%) 8 (1·4%) 1·10 (0·43–2·86) 0·8
Invasive 6 (1·1%) 5 (1·0%) 1·17 (0·36–3·84) 0·8
DCIS 2 (0·2%) 3 (0·4%) 0·66 (0·11–3·96) 0·7
Unknown 1 0 ·· ··
All 
unknown†
1 5 ·· ··
All new 
breast 
events
28 (5·4%) 59 (11·7%) 0·44 (0·32–0·60) <0·0001
Data are number (%). DCIS=ductal carcinoma in situ. *Laterality or invasive 
unknown. †Laterality unknown. 
Table 3: New breast events and 10-year estimates of percentages with 
an event in patients according to radiotherapy randomisation
Figure 4: Kaplan-Meier curve for cumulative incidence and annual hazard 
plot of all breast events in the radiotherapy comparison
Number at risk
Radiotherapy
No radiotherapy
0
0
5
10
15
20
25
Pa
tie
nt
s w
ith
 a
 n
ew
 b
re
as
t e
ve
nt
 (%
)
30 No radiotherapy
Radiotherapy
5 10
Follow-up (years)
15 20
522
508
431
486
341
404
93
102
An
nu
al
 h
az
ar
d 
ra
te
s (
%
)
6 8 10 12 140
1
2
3
4
2 4
Follow-up (years)
0
Articles
26 www.thelancet.com/oncology   Vol 12   January 2011
analysis because of protocol violations; two patients had 
previous malignant disease, four patients underwent 
mastectomy before randomisation, and one patient had 
invasive cancer rather than DCIS. 59 patients had micro-
invasive disease and 130 patients were on hormone 
replacement therapy at time of randomisation. Because 
neither factor was confounding, these patients were 
included in the analysis. Thus, 1694 patients were eligible 
for analysis (ﬁ gure 1).
Follow-up was complete up to Oct 1, 2008, and events 
after that time are not included in this analysis. Median 
follow-up was 12·7 years (IQR 10·9–14·7). 1363 (80%) of 
1694 patients were 50–64 years old and 160 (9%) were 
under 50 years old at randomisation; these patients had 
either symptomatic or mammographically detected DCIS.
912 patients (54%) chose to enter the 2×2 randomisation 
(ﬁ gure 1). 782 patients chose the two-way randomisation: 
664 patients (39%) were randomly assigned to receive 
tamoxifen or not, of whom 603 elected not to receive 
radiotherapy and 61 received elective radiotherapy; 
118 patients (7%) were randomly assigned to receive 
radiotherapy or not, of whom 29 elected not to receive 
tamoxifen and 89 received elective tamoxifen.
376 (22·2%) women had new breast events during the 
follow-up period (table 1): 197 (12%) patients had ductal 
carcinoma in situ (DCIS), 163 (10%) had invasive 
cancers, and the type of new breast events was unknown 
in 16 (1%).
In total, 1576 patients were randomly assigned to 
receive tamoxifen or not (ﬁ gure 1). 342 of these women 
developed a new breast event: 188 DCIS and 154 an 
invasive carcinoma (table 2). Fewer new breast events 
occurred in the patients randomly assigned to receive 
tamoxifen than in those who did not receive the drug 
(p=0·002; table 2; ﬁ gure 2). Tamoxifen signiﬁ cantly 
reduced the rate of recurrent ipsilateral DCIS but not 
ipsilateral invasive disease (table 2). An absolute 10-year 
reduction of 3·9% was reported for all ipsilateral events. 
There was a signiﬁ cant reduction in all contralateral 
events in those randomly assigned to tamoxifen 
compared with those assigned to no tamoxifen 
(p=0·005; table 2), with an absolute 10-year reduction of 
2·3%. Tamoxifen was associated with a reduction in the 
incidence of contralateral invasive events and there was 
weak evidence of a reduction in incidence of DCIS 
(table 2). Overall, an absolute 10-year reduction of 6·5% 
for all new breast events was achieved with the use of 
tamoxifen.
Women who were randomly assigned to tamoxifen but 
who were not treated with radiotherapy had a signiﬁ cant 
overall reduction in new breast events (p=0·001), whereas 
Figure 5: Forest plot for new breast events in the radiotherapy comparison stratiﬁ ed by whether or not 
patients received tamoxifen
HR=hazard ratio. DCIS=ductal carcinoma in situ.
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10/522
9/522
19/522
6/522
2/522
9/522
28/522
22/508
22/508
46/508
5/508
3/508
8/508
59/508
0·44 (0·21–0·93)
0·35 (0·16–0·78)
0·37 (0·22–0·64)
1·17 (0·36–3·84)
0·66 (0·11–3·96)
1·10 (0·43–2·86)
0·44 (0·32–0·60)
0·1 0·2
Favours radiotherapy Favours no radiotherapy
0·5 1 2
Randomised to 
tamoxifen
Randomised to no 
tamoxifen
Hazard ratio (95% CI) Randomised to 
radiotherapy
Randomised to no 
radiotherapy
Hazard ratio (95% CI)
Grade
Low (n=105) 2/50 (4%) 11/45 (24%) 0·15 (0·03–0·68) 3/33 (6%) 4/34 (12%) 0·78 (0·18–3·50)
Intermediate (n=267) 12/124 (9%) 24/125 (19%) 0·44 (0·22–0·90) 3/79 (4%) 19/83 (22%) 0·13 (0·04–0·51)
High (n=1014) 112/475 (22%) 138/467 (27%) 0·79 (0·62–1·02) 44/327 (12%) 87/294 (26%) 0·40 (0·27–0·58)
Age (years)
<50 (n=160) 18/77 (22%) 27/69 (35%) 0·58 (0·32–1·07) 13/45 (27%) 16/56 (23%) 0·96 (0·45–2·03)
50–60 (n=919) 87/434 (19%) 102/425 (22%) 0·84 (0·63–1·12) 29/290 (9%) 74/275 (25%) 0·34 (0·22–0·52)
>60 (n=615) 46/283 (16%) 75/288 (25%) 0·59 (0·40–0·85) 18/187 (9%) 39/177 (20%) 0·39 (0·22–0·69)
Data are n/N (%).
Table 4: All new breast events and 10-year estimates of percentages with an event in patients according to grade and age
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there was no apparent beneﬁ t among those who received 
radiotherapy (p=0·8; table 2; ﬁ gure 3).
In total, 1030 patients were randomly assigned to receive 
radiotherapy or not (ﬁ gure 1). 189 of these patients 
developed a new breast event: 89 DCIS and 93 an invasive 
carcinoma (table 3). Overall, those randomised to radio-
therapy had fewer new breast events than did those not 
randomised to radiotherapy (p<0·0001; table 3; ﬁ gure 4), 
with an absolute reduction of 12·6%. Radiotherapy 
signiﬁ cantly reduced all ipsilateral events (p<0·0001) 
whereas no eﬀ ect of radiotherapy was reported in relation 
to contralateral events (p=0·6). In both patients who 
received tamoxifen and those who did not, a signiﬁ cant 
reduction in new breast events was reported with 
radiotherapy (table 3; ﬁ gure 5). 
242 women were randomised to receive tamoxifen and 
radiotherapy. 25 of these patients developed a new breast 
event: ten DCIS and 14 an invasive cancer (one unknown). 
In an analysis restricted to patients in the factorial 
randomisation, the combination treatment signiﬁ cantly 
reduced new breast events compared with no adjuvant 
treatment (p<0·0001). Tamoxifen plus radiotherapy 
signiﬁ cantly reduced all ipsilateral new breast events 
(p<0·0001) but had no eﬀ ect on contralateral new breast 
events (p=0·2; webappendix p 1). There were no 
signiﬁ cant diﬀ erences in new breast events between 
patients randomly assigned to radiotherapy and 
tamoxifen and those randomised to radiotherapy alone 
(webappendix p 2). Patients randomised to radiotherapy 
and tamoxifen had signiﬁ cantly reduced ipsilateral new 
breast events compared with those randomised to 
tamoxifen alone (p<0·0001) but not contralateral new 
breast events (p=0·5; webappendix p 3). 
Tumour blocks were not collected at trial entry, but 
diagnostic slides have now been collected retrospectively 
and centrally reviewed for 1224 of the 1694 patients,16 
which suggested that high grade, large size, and young 
age were signiﬁ cant predictors of a high recurrence 
rate.16 Table 4 shows details of potential treatment 
interactions with age and tumour grade. Tamoxifen 
seemed to be more eﬀ ective in women with a low-grade 
or intermediate-grade tumours compared with those 
with a high-grade tumour. There was a weak eﬀ ect of 
radiotherapy in those with intermediate-grade or high-
grade tumours. No clear eﬀ ect of age was seen on 
tamoxifen eﬃ  cacy, whereas radiotherapy was more 
eﬀ ective in women over 50 years old than in those 
under 50 years old.
179 women had died after a median of 12·7 years of 
follow-up (table 5). Overall, there was no signiﬁ cant 
diﬀ erence in the death rate across treatment groups, 
but an increase cardiovascular deaths was reported in 
those randomised to radiotherapy, with or without 
tamoxifen (p=0·008), although the numbers were 
small. Deaths from breast cancer seemed to be slightly 
higher in the tamoxifen group, but this diﬀ erence was 
not signiﬁ cant.
Discussion
These updated results from the UK/ANZ DCIS trial 
conﬁ rm that radiotherapy signiﬁ cantly reduces the 
relative risk of ipsilateral new breast events in women 
with DCIS and suggest that the eﬀ ect is long lasting 
(panel). Additionally, these results provide evidence that 
tamoxifen reduces new breast events in women with 
locally excised DCIS. The clinically most relevant 
endpoints are invasive ipsilateral new breast events for 
radiotherapy because it is a local therapy, and all breast 
events for tamoxifen because it is a systemic therapy. This 
is now standard practice, but it was not prespeciﬁ ed in 
the protocol, which was written in 1989. Designation of 
these as endpoints of primary interest occurred before 
the present analyses were undertaken, but this decision 
was not documented in a formal statistical analysis plan. 
In our ﬁ rst report,10 there was no signiﬁ cant reduction in 
new breast events with tamoxifen; however, in this long-
term follow-up the reduction in new breast events was 
signiﬁ cant. No eﬀ ect was identiﬁ ed on ipsilateral invasive 
new breast events and the largest eﬀ ect was on 
contralateral new breast events. The tamoxifen eﬀ ect 
seemed to be apparent only in patients who did not 
receive radiotherapy; however, only 523 patients who 
received radiotherapy were in the tamoxifen 
randomisation and a test for interaction between 
treatments was not signiﬁ cant (data not shown). An eﬀ ect 
of tamoxifen was seen in irradiated patients in the only 
other trial that assessed its use in women with DCIS.11
No adjuvant 
treatment (n=544)
Tamoxifen 
(n=567)
Radiotherapy 
(n=267)
Radiotherapy and 
tamoxifen (n=316)
Total 
(n=1694)
Breast cancer 11 (2%) 19 (3%) 4 (1%) 5 (2%) 39 (2%)
Other cancer 14 (3%) 19 (3%) 10 (4%) 14 (4%) 57 (3%)
Cardiovascular 1 (0%) 3 (1%) 5 (2%) 3 (1%) 12 (1%)
Cerebrovascular 3 (1%) 1 (0%) 0 2 (1%) 6 (0%)
Thromboembolic 3 (1%) 1 (0%) 0 2 (1%) 6 (0%)
Other 20 (4%) 15 (3%) 7 (3%) 17 (5%) 59 (3%)
Total 52 (10%) 58 (10%) 26 (10%) 43 (14%) 179 (11%)
Table 5: Causes of death
Entry dates Number randomised Median follow-up 
(years)
HR (95% CI) for 
ipsilateral new breast 
events
Radiotherapy (50 Gy in 25 fractions recommended)
NSABP B-177 1985–90 818 10·7 RR 0·43 (p<0·0001) 
EORTC 108539,17 1986–96 1010 10·5 0·53 (0·40–0·70)
UK/ANZ10 1990–98 1030 12·7 0·32 (0·22–0·47)
Swedish18 1987–99 1067 8·0 0·40 (0·30–0·54)
Tamoxifen (20 mg for 5 years)
NSABP B-2414 1991–94 1804 7·0 0·70 (0·50–0·98)
UK/ANZ10 1990–98 1576 12·7 0·71 (0·58–0·88)
HR=hazard ratio. RR=risk ratio. 
Table 6: Trials of the treatment of ductal carcinoma in situ
See Online for webappendix
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Only 130 (8%) patients were on hormone-replacement 
therapy at the time of randomisation. Of these, 19 (29·2%) 
of 65 randomised to tamoxifen developed a new breast 
event compared with 16 (24·6%) of 65 who were not on 
tamoxifen. However, we do not have adequate data on the 
use of hormone-replacement therapy during the trial to 
be able to reliably draw conclusions from these data.
At present, the NSABP B-24 trial14 is the only other 
study that has assessed the use tamoxifen in DCIS. All 
women received radiotherapy and tamoxifen signiﬁ cantly 
reduced recurrences after just over 6 years of follow-up 
(rate ratio 0·63, 95% CI 0·47–0·83), with weak evidence 
of a reduction in recurrent DCIS (0·69, 0·46–1·04) and a 
signiﬁ cant reduction in invasive breast cancer events 
(0·57, 0·38–0·85). By contrast with our study, a signiﬁ cant 
reduction in invasive ipsilateral tumours was reported 
with tamoxifen in these irradiated patients. A possible 
explanation for the diﬀ erence is the younger average age 
of the women in the NSABP study: in our study, over 
90% were aged 50 years or more compared with 34% in 
the NSABP B-177 and B-2414 trials.
Our updated ﬁ ndings regarding new breast events from 
the radiotherapy comparison conﬁ rm previous ﬁ ndings.7,9–11 
We noted a slightly larger reduction in ipsilateral new 
breast events (HR 0·32, 95% CI 0·19–0·56) compared 
with our previous report (0·38, 0·25–0·59).10 The eﬀ ect of 
radiotherapy was similar whether or not patients received 
tamoxifen. The European Organisation for Research and 
Treatment of Cancer (EORTC) trial17 reported updated 
results on the use of radiotherapy in DCIS in the absence 
of tamoxifen after a median of 10·5 years of follow-up. 
A HR for recurrence of 0·53 was reported, which is 
consistent with the HR of 0·41 we noted in women 
randomised to radiotherapy who did not receive tamoxifen 
compared with those who did not have radiotherapy. The 
NSABP B-17 trial reported the updated results of the eﬀ ects 
of radiotherapy after 12 years of follow-up.11 The HR for all 
breast events was 0·59 in women randomised to 
radiotherapy compared with those who were not. 
A Swedish study18 reported a relative risk of 0·40 for 
ipsilateral disease in women who received radiotherapy 
compared with those not irradiated, corresponding to an 
absolute 10-year reduction of 16%. This reduction is similar 
to that reported in our study. Furthermore, this study also 
conﬁ rms our ﬁ nding that older women beneﬁ t more from 
radiotherapy than younger women. The absence of any 
new breast events in the radiotherapy groups of the 
UK/ANZ DCIS trial after 9 years (data not shown) diﬀ ers 
from the other trials, where the rate appears to be constant, 
albeit lower than in those not irradiated. This could be a 
chance ﬁ nding based on small numbers. 
The Early Breast Cancer Trialists’ Collaborative Group 
did a meta-analysis of the eﬀ ects of radiotherapy on local 
recurrences and 15-year survival in women with early 
invasive breast cancer.22 Overall, the recurrence rate ratio 
was about 0·3 in women receiving radiotherapy after 
breast-conserving surgery compared with those not 
receiving radiotherapy. This reduction is again similar to 
that reported in the present analysis.
No signiﬁ cant eﬀ ects were reported on mortality, either 
from breast cancer or other causes for either treatment, 
except for a possible detrimental eﬀ ect of radiotherapy 
on cardiovascular deaths, but the numbers were small 
and further data are needed.
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